Recombinant interleukin 12 (IL-12) can profoundly suppress cellular immune responses in mice. To define the underlying mechanism, recombinant murine (rm)IL-12 was given to C57BL/6 mice undergoing alloimmunization and found to transiently but profoundly suppress in vivo and in vitro allogeneic responses and in vitro splenocyte mitogenic responses. Use of neutralizing antibodies and genetically deficient mice showed that IFN-γ (but not TNF-α) mediated rmIL-12–induced immune suppression. Splenocyte fractionation studies revealed that adherent cells from rmIL-12–treated mice suppressed the mitogenic response of normal nonadherent cells to concanavalin A and IL-2. Addition of an inhibitor of nitric oxide synthase (NOS) restored mitogenic responses, and inducible (i)NOS−/− mice were not immunosuppressed by rmIL-12. These results support the view that suppression of T cell responses is due to NO produced by macrophages responding to the high levels of IFN-γ induced by rmIL-12. When a NOS inhibitor was given with rmIL-12 during vaccination of A/J mice with irradiated SCK tumor cells, immunosuppression was averted and the extent of rmIL-12's ability to enhance induction of protective antitumor immunity was revealed. This demonstrates that rmIL-12 is an effective vaccine adjuvant whose efficacy may be masked by its transient immunosuppressive effect.
Skip Nav Destination
Article navigation
2 November 1998
Article|
November 02 1998
Immune Suppression by Recombinant Interleukin (rIL)-12 Involves Interferon γ Induction of Nitric Oxide Synthase 2 (iNOS) Activity: Inhibitors of NO Generation Reveal the Extent of rIL-12 Vaccine Adjuvant Effect
Holly Kurzawa Koblish,
Holly Kurzawa Koblish
From the *Cell and Molecular Biology Graduate Group and the ‡Department of Medicine, Cancer Center, and Institute for Human Gene Therapy, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; the §School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; and ‖The Wistar Institute, Philadelphia, Pennsylvania 19104
Search for other works by this author on:
Christopher A. Hunter,
Christopher A. Hunter
From the *Cell and Molecular Biology Graduate Group and the ‡Department of Medicine, Cancer Center, and Institute for Human Gene Therapy, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; the §School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; and ‖The Wistar Institute, Philadelphia, Pennsylvania 19104
Search for other works by this author on:
Maria Wysocka,
Maria Wysocka
From the *Cell and Molecular Biology Graduate Group and the ‡Department of Medicine, Cancer Center, and Institute for Human Gene Therapy, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; the §School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; and ‖The Wistar Institute, Philadelphia, Pennsylvania 19104
Search for other works by this author on:
Giorgio Trinchieri,
Giorgio Trinchieri
From the *Cell and Molecular Biology Graduate Group and the ‡Department of Medicine, Cancer Center, and Institute for Human Gene Therapy, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; the §School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; and ‖The Wistar Institute, Philadelphia, Pennsylvania 19104
Search for other works by this author on:
William M.F. Lee
William M.F. Lee
From the *Cell and Molecular Biology Graduate Group and the ‡Department of Medicine, Cancer Center, and Institute for Human Gene Therapy, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; the §School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; and ‖The Wistar Institute, Philadelphia, Pennsylvania 19104
Search for other works by this author on:
Holly Kurzawa Koblish
From the *Cell and Molecular Biology Graduate Group and the ‡Department of Medicine, Cancer Center, and Institute for Human Gene Therapy, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; the §School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; and ‖The Wistar Institute, Philadelphia, Pennsylvania 19104
Christopher A. Hunter
From the *Cell and Molecular Biology Graduate Group and the ‡Department of Medicine, Cancer Center, and Institute for Human Gene Therapy, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; the §School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; and ‖The Wistar Institute, Philadelphia, Pennsylvania 19104
Maria Wysocka
From the *Cell and Molecular Biology Graduate Group and the ‡Department of Medicine, Cancer Center, and Institute for Human Gene Therapy, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; the §School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; and ‖The Wistar Institute, Philadelphia, Pennsylvania 19104
Giorgio Trinchieri
From the *Cell and Molecular Biology Graduate Group and the ‡Department of Medicine, Cancer Center, and Institute for Human Gene Therapy, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; the §School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; and ‖The Wistar Institute, Philadelphia, Pennsylvania 19104
William M.F. Lee
From the *Cell and Molecular Biology Graduate Group and the ‡Department of Medicine, Cancer Center, and Institute for Human Gene Therapy, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; the §School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; and ‖The Wistar Institute, Philadelphia, Pennsylvania 19104
Address correspondence to William M.F. Lee, 663 Clinical Research Building, 415 Curie Blvd., University of Pennsylvania, Philadelphia, PA 19104-6140. Phone: 215-898-0258; Fax: 215-573-7912; E-mail: leemingf @mail.med.upenn.edu
Received:
April 27 1998
Revision Received:
August 10 1998
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1998
J Exp Med (1998) 188 (9): 1603–1610.
Article history
Received:
April 27 1998
Revision Received:
August 10 1998
Citation
Holly Kurzawa Koblish, Christopher A. Hunter, Maria Wysocka, Giorgio Trinchieri, William M.F. Lee; Immune Suppression by Recombinant Interleukin (rIL)-12 Involves Interferon γ Induction of Nitric Oxide Synthase 2 (iNOS) Activity: Inhibitors of NO Generation Reveal the Extent of rIL-12 Vaccine Adjuvant Effect . J Exp Med 2 November 1998; 188 (9): 1603–1610. doi: https://doi.org/10.1084/jem.188.9.1603
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement